Director Gary B. Gordon filed a Form 4 with the SEC on November 19, 2026, disclosing a purchase of 10,000 shares of TriSalus Life Sciences, Inc. common stock on November 17, 2026.
Key Highlights
- Reporting person: Gary B. Gordon, identified as a Director of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)
- Transaction: Purchase (transaction code P) of 10,000 shares of common stock on November 17, 2026
- Price paid: $2.20 per share, according to the filing
- Resulting ownership: 82,510 shares of common stock held directly following the transaction
- No derivative securities: Table II of the filing contains no reported derivative security transactions
Gordon's Open-Market Purchase of TriSalus Common Stock
According to the Form 4 filed on November 19, 2026, Gary B. Gordon, a director of TriSalus Life Sciences, Inc., acquired 10,000 shares of the company's common stock on November 17, 2026 at a price of $2.20 per share. The transaction is recorded with code "P," indicating an open-market purchase. The filing reports that Gordon's direct beneficial ownership of common stock stood at 82,510 shares following the transaction.
The filing was signed by Mary Szela as attorney-in-fact on behalf of Gordon, and was submitted on November 19, 2026. Gordon's address is listed as 6272 W. 91st Avenue, Westminster, Colorado 80031. No amendment date is indicated, and the form was filed by one reporting person. Table II, covering derivative securities such as options, warrants, or convertible securities, contains no entries.
The filing notes no Rule 10b5-1(c) plan designation for this transaction, and Gordon's relationship to the issuer is listed solely as Director. No 10% owner or officer designation is checked on the form.
What Was Disclosed
Director Gary B. Gordon reported a direct purchase of 10,000 shares of TriSalus Life Sciences, Inc. common stock at $2.20 per share on November 17, 2026, bringing his directly held total to 82,510 shares, with no derivative securities reported.



Please wait processing your request...